Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study-February 2024-www.financetom.com

Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study

Aug 13, 2025 5:52 AM

08:17 AM EDT, 08/13/2025 (MT Newswires) -- Ocugen ( OCGN ) said Wednesday that the European Medicines Agency's Committee for Medicinal Products for Human Use provided acceptability for a phase 2/3 trial of OCU410ST to submit for a marketing authorization application.

The company said the acceptance is based on results from its phase 1 GARDian trial. It added that the trial is intended to study its modifier gene therapy of OCU410ST to treat Stargardt disease, a genetic eye condition.

Shares of the company fell 1% in recent premarket activity Wednesday.

Previous page： BRIEF-Oklo Announces Proposed Acquisition Of Atomic Alchemy To Expand Into Radioisotope Market Next page： ArriVent BioPharma's Q3 Net Loss Narrows

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Oklo Announces Proposed Acquisition Of Atomic Alchemy To Expand Into Radioisotope Market

Nov 15, 2024

Nov 14 (Reuters) - Oklo Inc ( OKLO ): * OKLO ANNOUNCES PROPOSED ACQUISITION OF ATOMIC ALCHEMY TO EXPAND INTO RADIOISOTOPE MARKET * OKLO INC ( OKLO ) - TO ACQUIRE ATOMIC ALCHEMY FOR $25 MILLION IN ALL-STOCK DEAL Source text: Further company coverage: ...

ArriVent BioPharma's Q3 Net Loss Narrows

Nov 15, 2024

08:29 AM EST, 11/14/2024 (MT Newswires) -- ArriVent BioPharma ( AVBP ) reported a Q3 net loss Thursday of $0.61 per diluted share, narrowing from a loss of $5.52 a year earlier. Analysts polled by Capital IQ expected a loss of $0.82 per share. As expected, no revenue for the quarter ended Sept. 30 was reported. As of Sept. 30,...

Boralex Q3 Loss Widens on Weaker Renewable Power Production and Lower Revenue

Nov 15, 2024

08:26 AM EST, 11/14/2024 (MT Newswires) -- Boralex ( BRLXF ) on Thursday said its second quarter loss widened on lower electricity production and weaker revenue. The renewable-power producer said it lost $14 million, in the quarter, compared with a loss of $8 million in the year-prior period. Per-share results were not disclosed. Revenue fell 12% to $150 million from...

UK regulator to start in-depth probe into GXO's $962 mln Wincanton deal

Nov 15, 2024

Nov 14 (Reuters) - Britain's competition regulator said on Thursday it referred GXO Logistics' ( GXO ) acquisition of UK peer Wincanton to an in-depth investigation after the U.S.-based warehousing firm did not present remedies for competition concerns. CONTEXT GXO outbid CEVA, a unit of French shipping firm CMA CGM, to buy the British logistics firm for 762 million pounds...